Guangdong Jiaying Pharmaceutical Co., Ltd (SHE:002198)
6.94
+0.08 (1.17%)
Feb 3, 2026, 3:04 PM CST
SHE:002198 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 409.24 | 375.41 | 533.03 | 659.03 | 574.28 | 543.85 |
Other Revenue | 0.76 | 0.76 | 0.2 | 0.17 | 0.44 | 0.88 |
| 410 | 376.17 | 533.23 | 659.2 | 574.71 | 544.73 | |
Revenue Growth (YoY) | -1.35% | -29.45% | -19.11% | 14.70% | 5.50% | 8.84% |
Cost of Revenue | 169.27 | 151.91 | 186.34 | 229.22 | 143.26 | 148.08 |
Gross Profit | 240.73 | 224.25 | 346.9 | 429.98 | 431.45 | 396.65 |
Selling, General & Admin | 175.79 | 185.89 | 292.82 | 351.17 | 379.1 | 346.89 |
Research & Development | 8.34 | 6.76 | 10.1 | 15.34 | 14.4 | 9.38 |
Other Operating Expenses | 7.96 | 7.19 | 9.07 | 10.59 | 10.67 | 9.51 |
Operating Expenses | 197.08 | 203.88 | 311.34 | 379.76 | 402.16 | 366.85 |
Operating Income | 43.65 | 20.37 | 35.56 | 50.22 | 29.29 | 29.8 |
Interest Expense | -0 | -0 | -0 | -0.45 | -1.02 | -3.99 |
Interest & Investment Income | 0.71 | 2.08 | 2.7 | 2.74 | 3.67 | 1.32 |
Earnings From Equity Investments | - | - | - | - | - | -3.64 |
Other Non Operating Income (Expenses) | -0.06 | -0.02 | 0.01 | -0 | 1.48 | -0.03 |
EBT Excluding Unusual Items | 44.3 | 22.44 | 38.27 | 52.5 | 33.42 | 23.46 |
Gain (Loss) on Sale of Investments | -0.24 | - | 0.53 | 0.26 | -28.8 | - |
Gain (Loss) on Sale of Assets | -0.13 | 1.61 | 0.14 | -0.01 | -0.19 | -0.03 |
Asset Writedown | 0.85 | - | - | - | -0.01 | -0.02 |
Other Unusual Items | 1.25 | 1.05 | 0.44 | -1.65 | 1.39 | -0.39 |
Pretax Income | 46.03 | 25.1 | 39.37 | 51.1 | 5.82 | 23.02 |
Income Tax Expense | 6.5 | 4.48 | 5.05 | 7.16 | 4.35 | 3.18 |
Net Income | 39.53 | 20.61 | 34.32 | 43.93 | 1.48 | 19.84 |
Net Income to Common | 39.53 | 20.61 | 34.32 | 43.93 | 1.48 | 19.84 |
Net Income Growth | 221.73% | -39.94% | -21.88% | 2874.04% | -92.55% | - |
Shares Outstanding (Basic) | 511 | 508 | 508 | 507 | 509 | 507 |
Shares Outstanding (Diluted) | 511 | 508 | 508 | 507 | 509 | 507 |
Shares Change (YoY) | 1.05% | -0.00% | 0.07% | -0.41% | 0.40% | -0.01% |
EPS (Basic) | 0.08 | 0.04 | 0.07 | 0.09 | 0.00 | 0.04 |
EPS (Diluted) | 0.08 | 0.04 | 0.07 | 0.09 | 0.00 | 0.04 |
EPS Growth | 218.40% | -39.94% | -21.94% | 2886.21% | -92.58% | - |
Free Cash Flow | -79.87 | 22.14 | 93.39 | 24.41 | 49.46 | 85.19 |
Free Cash Flow Per Share | -0.16 | 0.04 | 0.18 | 0.05 | 0.10 | 0.17 |
Dividend Per Share | - | - | 0.050 | - | - | - |
Gross Margin | 58.71% | 59.61% | 65.05% | 65.23% | 75.07% | 72.82% |
Operating Margin | 10.64% | 5.42% | 6.67% | 7.62% | 5.10% | 5.47% |
Profit Margin | 9.64% | 5.48% | 6.44% | 6.67% | 0.26% | 3.64% |
Free Cash Flow Margin | -19.48% | 5.89% | 17.51% | 3.70% | 8.61% | 15.64% |
EBITDA | 59.7 | 39.92 | 59.77 | 76.11 | 57.69 | 57.99 |
EBITDA Margin | 14.56% | 10.61% | 11.21% | 11.55% | 10.04% | 10.64% |
D&A For EBITDA | 16.05 | 19.55 | 24.21 | 25.89 | 28.4 | 28.19 |
EBIT | 43.65 | 20.37 | 35.56 | 50.22 | 29.29 | 29.8 |
EBIT Margin | 10.64% | 5.42% | 6.67% | 7.62% | 5.10% | 5.47% |
Effective Tax Rate | 14.11% | 17.87% | 12.83% | 14.02% | 74.63% | 13.83% |
Revenue as Reported | 410 | 376.17 | 533.23 | 659.2 | 574.71 | 544.73 |
Advertising Expenses | - | 59.46 | 52.85 | 63.8 | 59.47 | 52.34 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.